Observational studyCritical care (London, England)2020
Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness.
Observational study in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04974775 (Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Trial
- The role of cellular senescence in sepsis and its mechanism in copper death: An analysis based on machine learning.Medicine · 2026Article
- Update on sepsis treatment.Journal of intensive care · 2026Review
- Immune Endotype-Guided Precision Immunotherapy in Sepsis: From Transcriptomics to Bedside Application.Cureus · 2026Review
- MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis.Circulation · 2026Article
- Bioactive adrenomedullin as a point-of-care biomarker in emergency department patients with suspected severe infections: an exploratory analysis.BMC infectious diseases · 2026Article
- Multi-Marker Approach in Sepsis: A Clinical Role Beyond SOFA Score.Medicina (Kaunas, Lithuania) · 2026Article
- Clinical Value of Galectin-9, Soluble TREM-1, and Soluble CD25 Among Critically Ill Patients with Organ Failure in the Emergency Department: A Prospective Observational Study.Diagnostics (Basel, Switzerland) · 2025Article
- Early Use of Innovative Biomarkers Such as Mid-Regional Pro-Adrenomedullin and SeptiCyteInternational journal of molecular sciences · 2025Article
- Immunodynamic Disruption in Sepsis: Mechanisms and Strategies for Personalized Immunomodulation.Biomedicines · 2025Review
- The association between week-one red blood cell distribution width and one-year survival in critically ill patients: propensity score-based multicenter analysis.European journal of medical research · 2025Article
- Bio-Adrenomedullin and Dipeptidyl Peptidase 3 as Novel Sepsis Biomarkers in the Emergency Department and the Intensive Care Unit: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Current and novel biomarkers in cardiogenic shock.European journal of heart failure · 2025Review
- Optical Bionanosensors for Sepsis Diagnostics.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Recent advances in understanding oxidative stress in sepsis: pathogenic roles and antioxidant therapeutic prospects - a narrative review.Frontiers in pharmacology · 2025Review
- Sandwich immunoassay for adrenomedullin precursor and its practical application.Scientific reports · 2024Article
- Bioactive Adrenomedullin in Dogs with Sepsis and Septic Shock: A Prospective, Case-Control Study.Animals : an open access journal from MDPI · 2024Article
- Plasma bioactive adrenomedullin predicts mortality and need for dialysis in critical COVID-19.Scientific reports · 2024Article
- Advanced biomarker clustering analysis reveals mortality predictors in burn patients with sepsis.Scientific reports · 2024Article
- Sepsis Biomarkers: Advancements and Clinical Applications-A Narrative Review.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiomarkers can be of help to understand critical illness and to identify and stratify sepsis. Adrenomedullin is a vasoactive hormone, with reported prognostic and potentially therapeutic value in sepsis. The primary aim of this study was to investigate the association of circulating bioactive adrenomedullin (bio-ADM) levels at intensive care unit (ICU) admission with mortality in sepsis patients and in a general ICU population. Secondary aims included the association of bio-ADM with organ failure and the ability of bio-ADM to identify sepsis.
methodsIn this retrospective observational study, adult patients admitted to one of four ICUs during 2016 had admission bio-ADM levels analysed. Age-adjusted odds ratios (OR) with 95% CI for log-2 transformed bio-ADM, and Youden's index derived cut-offs were calculated. The primary outcome was 30-day mortality, and secondary outcomes included the need for organ support and the ability to identify sepsis.
resultsBio-ADM in 1867 consecutive patients were analysed; 632 patients fulfilled the sepsis-3 criteria of whom 267 had septic shock. The median bio-ADM in the entire ICU population was 40 pg/mL, 74 pg/mL in sepsis patients, 107 pg/mL in septic shock and 29 pg/mL in non-septic patients. The association of elevated bio-ADM and mortality in sepsis patients and the ICU population resulted in ORs of 1.23 (95% CI 1.07-1.41) and 1.22 (95% CI 1.12-1.32), respectively. The association with mortality remained after additional adjustment for lactate in sepsis patients. Elevated bio-ADM was associated with an increased need for dialysis with ORs of 2.28 (95% CI 2.01-2.59) and 1.97 (95% CI 1.64-2.36) for the ICU population and sepsis patients, respectively, and with increased need of vasopressors, OR 1.33 (95% CI 1.23-1.42) (95% CI 1.17-1.50) for both populations. Sepsis was identified with an OR of 1.78 (95% CI 1.64-1.94) for bio-ADM, after additional adjustment for severity of disease. A bio-ADM cut-off of 70 pg/mL differentiated between survivors and non-survivors in sepsis, but a Youden's index derived threshold of 108 pg/mL performed better.
conclusionsAdmission bio-ADM is associated with 30-day mortality and organ failure in sepsis patients as well as in a general ICU population. Bio-ADM may be a morbidity-independent sepsis biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.